Experienced in Cardiomyopathy Due to Anthracyclines

Blanca Boluda

Avda. Fernando Abril Martorell 106, CP, 
Valencia, VC, ES 
Experienced in Cardiomyopathy Due to Anthracyclines
Avda. Fernando Abril Martorell 106, CP, 
Valencia, VC, ES 
OverviewLocationsClinical Research

Overview

Blanca Boluda practices in Valencia, Spain. Ms. Boluda is rated as an Experienced expert by MediFind in the treatment of Cardiomyopathy Due to Anthracyclines. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Febrile Neutropenia, Leukocytosis, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 58 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Cardiomyopathy Due to Anthracyclines.

Gender
Female

Locations

Avda. Fernando Abril Martorell 106, CP, Valencia, VC 46026, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML
A 2:1 Randomized Phase II Trial to Compare the Efficacy and Safety of Standard Chemotherapy Plus Quizartinib Versus Standard Chemotherapy Plus Placebo in Adult Patients With Newly Diagnosed FLT3 Wild-type AML
Enrollment Status: Completed
Publish Date: September 02, 2025
Intervention Type: Drug
Study Drugs: Quizartinib, Cytarabine, Idarubicin
Study Phase: Phase 2
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
A Randomized Phase III, Multicentre, Open Label Clinical Trial Comparing Azacitidine Plus Pevonedistat Versus Azacitidine in Older/Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Pevonedistat, Azacitidine
Study Phase: Phase 3
View 1 Less Clinical Trial

58 Total Publications

Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study.
Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Boluda's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile